Skip to main content

ATRIAL VS VENTRICULAR SECONDARY MITRAL REGURGITATION

 

ATRIAL VS VENTRICULAR SECONDARY MITRAL REGURGITATION

Mechanisms, Echocardiographic Features, and Clinical Implications

INTRODUCTION


Secondary (functional) mitral regurgitation (SMR) occurs due to distortion of left heart geometry rather than primary mitral valve leaflet disease. Traditionally linked to left ventricular (LV) dysfunction, it is now clear that a distinct entity—atrial secondary mitral regurgitation (ASMR)—exists, driven predominantly by left atrial (LA) and mitral annular remodeling. Differentiating atrial from ventricular SMR is essential because mechanisms, prognosis, and management strategies differ significantly.



---


1. DEFINITIONS


Atrial Secondary Mitral Regurgitation (ASMR)


Mitral regurgitation caused by left atrial enlargement and mitral annular dilatation, with preserved or near-normal LV systolic function and minimal leaflet tethering.


Ventricular Secondary Mitral Regurgitation (VSMR)


Mitral regurgitation resulting from left ventricular dilatation and dysfunction, leading to papillary muscle displacement, leaflet tethering, and incomplete leaflet coaptation.



---


2. PATHOPHYSIOLOGY


Atrial Secondary MR


Chronic atrial fibrillation


Long-standing diastolic dysfunction


Heart failure with preserved ejection fraction (HFpEF)


Aging-related atrial remodeling



Key mechanism:


Mitral annular dilatation (especially posterior annulus)


Reduced annular contraction


Loss of atrioventricular coupling


Minimal leaflet tethering



Ventricular Secondary MR


Ischemic cardiomyopathy


Dilated cardiomyopathy


Heart failure with reduced ejection fraction (HFrEF)



Key mechanism:


LV remodeling → papillary muscle displacement


Apical and lateral leaflet tethering


Reduced closing forces


Increased tenting height and area




---


3. ECHOCARDIOGRAPHIC DIFFERENCES


Atrial SMR


Normal or mildly reduced LVEF


Marked left atrial enlargement


Dilated mitral annulus (often circular)


Minimal leaflet tethering


Central MR jet common


Normal LV size or mild concentric remodeling



Ventricular SMR


Reduced LVEF


Dilated LV with spherical remodeling


Increased tenting height and tenting area


Posteriorly directed or eccentric MR jets


Displaced papillary muscles




---


4. HEMODYNAMIC AND CLINICAL PROFILE


Feature Atrial SMR Ventricular SMR


LV systolic function Preserved Reduced

Primary driver LA / annulus LV remodeling

Common rhythm Atrial fibrillation Sinus rhythm or AF

Heart failure type HFpEF HFrEF

Pulmonary pressures Often elevated Often elevated

Prognostic driver Atrial disease burden LV dysfunction




---


5. MANAGEMENT IMPLICATIONS


Atrial Secondary MR


Aggressive rhythm control (AF ablation, cardioversion)


Optimization of diastolic function


Blood pressure control


Consider mitral annuloplasty or transcatheter edge-to-edge repair (TEER) in selected patients with refractory symptoms


Restoration of sinus rhythm may significantly reduce MR severity



Ventricular Secondary MR


Guideline-directed medical therapy for HFrEF


Cardiac resynchronization therapy when indicated


Transcatheter mitral valve repair (e.g., TEER) in symptomatic patients despite optimal medical therapy


Surgical intervention reserved for selected cases




---


6. PROGNOSIS


Atrial SMR: Prognosis closely linked to atrial fibrillation burden, pulmonary hypertension, and HFpEF progression. MR may improve with rhythm control.


Ventricular SMR: Prognosis primarily driven by LV dysfunction and adverse remodeling; MR often reflects advanced myocardial disease.




---


7. KEY TAKE-HOME POINTS


Atrial and ventricular secondary MR are distinct pathophysiological entities.


ASMR is driven by left atrial and annular remodeling, not LV dysfunction.


VSMR results from LV dilation and papillary muscle displacement.


Echocardiography is central to differentiation.


Management strategies differ and should target the primary remodeling chamber.




---


For more cardiology infographics and educational articles visit:

drmusmanjaved.com



Comments

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...